Abstract
Policy question: What is the incremental benefit of using higher valency (14-valent or higher) PCVs in children < 5 years of age?
- Population: Children aged < 5 years
- Intervention:
- Comparison(s): PCVs containing > 13 serotypes: PCV13 or PCV10
- Outcome: Invasive pneumococcal disease
Evidence to recommendation table
Pneumococcal disease
